No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Why Investors Shouldn't Be Surprised By Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Share Price Plunge
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $20
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $20 Price Target
Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23